A recently published report describes the case of a 61-year-old male patient who experienced antacid-induced hypercalcemia and highlights the importance of performing thorough medication reconciliation.
This report provides an update on the use of diagnostic tests for asymptomatic primary hyperparathyroidism in clinical practice.
Abrupt interruption or discontinuation of Natpara can result in severe hypocalcemia.
Parathyroidectomy may have a potential beneficial effect on lipid profiles and decrease cardiovascular risk in patients with primary hyperparathyroidism.
A greater increase in bone mineral density at the femoral neck may be seen after parathyroidectomy for sporadic primary hyperparathyroidism in men compared with women.
Intraoperative parathyroid hormone monitoring better predicts cure for primary hyperparathyroidism in parathyroidectomy than ultrasound and MIBI scans.
Patients with hypoparathyroidism have increased risk for several health conditions including cataracts, epilepsy, cardiovascular disease, cerebrovascular disease, infection, mental illness, and renal failure.
Markers of bone resorption decreased in hemodialysis patients with 6 months of etelcalcetide treatment.
In a study, patients receiving cinacalcet under supervision 3 times per week after dialysis rather than after daily self-administration showed improvement in their parathyroid hormone levels.
The rate of pre-eclampsia and preterm delivery was higher in medically managed patients with hyperparathyroidism.
Investigators sought to determine the effects of vitamin D3 supplementation in postmenopausal women with low serum 25(OH)D and high parathyroid hormone levels.